Metallothionein Isoforms as Double Agents - Their Roles in Carcinogenesis, Cancer Progression and Chemoresistance

Simple item page
dc.contributor"European Union (EU)" & "Horizon 2020"en
dc.contributor.authorMerlos Rodrigo, Miguel Ángelcs
dc.contributor.authorJimenez Jimenez, Ana Mariacs
dc.contributor.authorHaddad, Yazan Abdulmajeed Eyadhcs
dc.contributor.authorAdam, Pavlínacs
dc.contributor.authorKřížková, Soňacs
dc.contributor.authorHeger, Zbyněkcs
dc.contributor.authorAdam, Vojtěchcs
dc.coverage.issue1cs
dc.coverage.volume52cs
dc.date.accessioned2020-11-10T16:23:00Z
dc.date.available2020-11-10T16:23:00Z
dc.date.issued2020-09-30cs
dc.description.abstractMetallothioneins (MTs) are small cysteine-rich intracellular proteins with four major isoforms identified in mammals, designated MT-1 through MT-4. The best known biological functions of MTs are their ability to bind and sequester metal ions as well as their active role in redox homeostasis. Despite these protective roles, numerous studies have demonstrated that changes in MT expression could be associated with the process of carcinogenesis and participation in cell differentiation, proliferation, migration, and angiogenesis. Hence, MTs have the role of double agents, i.e., working with and against cancer. In view of their rich biochemical properties, it is not surprising that MTs participate in the emergence of chemoresistance in tumor cells. Many studies have demonstrated that MT overexpression is involved in the acquisition of resistance to anticancer drugs including cisplatin, anthracyclines, tyrosine kinase inhibitors and mitomycin. The evidence is gradually increasing for a cellular switch in MT functions, showing that they indeed have two faces: protector and saboteur. Initially, MTs display anti-oncogenic and protective roles; however, once the oncogenic process was launched, MTs are utilized by cancer cells for progression, survival, and contribution to chemoresistance. The duality of MTs can serve as a potential prognostic/diagnostic biomarker and can therefore pave the way towards the development of new cancer treatment strategies. Herein, we review and discuss MTs as tumor disease markers and describe their role in chemoresistance to distinct anticancer drugs.en
dc.description.embargo2021-03-05cs
dc.formattextcs
dc.format.extent1-13cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationDRUG RESISTANCE UPDATES. 2020, vol. 52, issue 1, p. 1-13.en
dc.identifier.doi10.1016/j.drup.2020.100691cs
dc.identifier.issn1368-7646cs
dc.identifier.other164638cs
dc.identifier.urihttp://hdl.handle.net/11012/195646
dc.language.isoencs
dc.publisherElseviercs
dc.relation.ispartofDRUG RESISTANCE UPDATEScs
dc.relation.projectIdinfo:eu-repo/grantAgreement/EC/H2020/759585/EU//ToMeTuMen
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S1368764620300182cs
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internationalcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/1368-7646/cs
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/cs
dc.subjectAnthracyclinesen
dc.subjectCanceren
dc.subjectChemoresistanceen
dc.subjectChemotherapeuticsen
dc.subjectCisplatinen
dc.subjectMetallomicsen
dc.subjectMetallothioneinsen
dc.subjectTyrosine kinase inhibitorsen
dc.titleMetallothionein Isoforms as Double Agents - Their Roles in Carcinogenesis, Cancer Progression and Chemoresistanceen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionacceptedVersionen
sync.item.dbidVAV-164638en
sync.item.dbtypeVAVen
sync.item.insts2021.03.05 00:55:23en
sync.item.modts2021.03.05 00:14:38en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
MetallothioneinIsoformsVUT.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format
Description:
MetallothioneinIsoformsVUT.pdf
Download
Collections
Chytré nanonástroje